Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
06 mars 2025 08h00 HE
|
Allarity Therapeutics, Inc.
Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans’ Administration Special Emphasis...
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
03 mars 2025 08h00 HE
|
Allarity Therapeutics, Inc.
Boston (March 3, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated...
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
26 févr. 2025 08h00 HE
|
Allarity Therapeutics, Inc.
Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated...
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
24 févr. 2025 08h00 HE
|
Allarity Therapeutics, Inc.
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA...
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
06 févr. 2025 08h00 HE
|
Allarity Therapeutics, Inc.
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a...
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
30 janv. 2025 08h00 HE
|
Allarity Therapeutics, Inc.
Boston (January 30, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
18 nov. 2024 08h00 HE
|
Allarity Therapeutics, Inc.
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s clinical...
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
14 nov. 2024 08h00 HE
|
Allarity Therapeutics, Inc.
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc....
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
22 oct. 2024 08h00 HE
|
Allarity Therapeutics, Inc.
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the Stenoparib DRP® are also pending in the US, Japan, China,...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
10 oct. 2024 08h00 HE
|
Allarity Therapeutics, Inc.
Boston (October 10, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...